Citations

Clear

1446 citation(s) found for "Howard, F".

Gene-Modified Mesenchymal Stem Cells Express Functionally Active Nerve Growth Factor on an Engineered Poly Lactic Glycolic Acid (PLGA) Substrate
Rooney, Gemma E., Moran, Cathal J., McMahon, Siobhán S. , Ritter, Thomas , Maenz, Martin, Flügel, Alexander , Dockery, Peter , O’Brien, Timothy , Howard, Linda , Windebank, Anthony J. , Barry, Frank

Mayo Clinic

Tissue Engineering Part A | April 11, 2008 | Volume: 14 | Issue: 5 | Pages: 681-690

10.1089/tea.2007.0260 | PMID 18402551 Get It

Robotics in Urology: Past, Present, and Future
Thiel, David D. , Winfield, Howard N.

Mayo Clinic

Journal of Endourology | March 10, 2008 | Volume: 22 | Issue: 4 | Pages: 825-830

10.1089/end.2007.9830 | PMID 18419224 Get It

In Reply
Höchster, Howard S. , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | February 28, 2008 | Volume: 26 | Issue: 7 | Pages: 1189-1189

10.1200/jco.2007.15.4369 Get It

Akt and CHIP coregulate tau degradation through coordinated interactions
Dickey, Chad A. , Koren, John , Zhang, Yong‐Jie , Xu, Ya-Fei, Jinwal, Umesh K., Birnbaum, Morris J. , Monks, Bobby R., Sun, Mei , Cheng, Jin , Patterson, Cam, Bailey, Rachel M. , Dunmore, Judith, Soresh, Sareh, Leon, Carlos M.M.P., Morgan, Dave, Petrucelli, Leonard , Zhang, Yong-Jie

Mayo Clinic

Proceedings of the National Academy of Sciences | February 21, 2008 | Volume: 105 | Issue: 9 | Pages: 3622-3627

10.1073/pnas.0709180105 | PMID 18292230 Get It

A hallmark of the pathology of Alzheimer's disease is the accumulation of the microtubule-associated protein tau into fibrillar aggregates. Recent studies suggest that they accumulate because cytosolic chaperones fail to clear abnormally phosphorylated tau, preserving a pool of toxic tau intermediates within the neuron. We describe a mechanism for tau clearance involving a major cellular kinase, Akt. During stress, Akt is ubiquitinated and degraded by the tau ubiquitin ligase CHIP, and this largely depends on the Hsp90 complex. Akt also prevents CHIP-induced tau ubiquitination and its subsequent degradation, either by regulating the Hsp90/CHIP complex directly or by competing as a client protein with tau for binding. Akt levels tightly regulate the expression of CHIP, such that, as Akt levels are suppressed, CHIP levels also decrease, suggesting a potential stress response feedback mechanism between ligase and kinase activity. We also show that Akt and the microtubule affinity-regulating kinase 2 (PAR1/MARK2), a known tau kinase, interact directly. Akt enhances the activity of PAR1 to promote tau hyperphosphorylation at S262/S356, a tau species that is not recognized by the CHIP/Hsp90 complex. Moreover, Akt1 knockout mice have reduced levels of tau phosphorylated at PAR1/MARK2 consensus sites. Hence, Akt serves as a major regulator of tau biology by manipulating both tau kinases and protein quality control, providing a link to several common pathways that have demonstrated dysfunction in Alzheimer's disease.
A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling
Wisler, James W., DeWire, Scott M. , Whalen, Erin J., Violin, Jonathan D., Ahn, Seungkirl , Shenoy, Sudha K. , Lefkowitz, Robert J. , Drake, Matthew T.

Mayo Clinic

Proceedings of the National Academy of Sciences | October 9, 2007 | Volume: 104 | Issue: 42 | Pages: 16657-16662

10.1073/pnas.0707936104 | PMID 17925438 Get It

For many years, β-adrenergic receptor antagonists (β-blockers or βAR antagonists) have provided significant morbidity and mortality benefits in patients who have sustained acute myocardial infarction. More recently, β-adrenergic receptor antagonists have been found to provide survival benefits in patients suffering from heart failure, although the efficacy of different β-blockers varies widely in this condition. One drug, carvedilol, a nonsubtype-selective βAR antagonist, has proven particularly effective in the treatment of heart failure, although the mechanism(s) responsible for this are controversial. Here, we report that among 16 clinically relevant βAR antagonists, carvedilol displays a unique profile of in vitro signaling characteristics. We observed that in β2 adrenergic receptor (β2AR)-expressing HEK-293 cells, carvedilol has inverse efficacy for stimulating G s -dependent adenylyl cyclase but, nonetheless, stimulates ( i ) phosphorylation of the receptor's cytoplasmic tail on previously documented G protein-coupled receptor kinase sites; ( ii ) recruitment of β-arrestin to the β2AR; ( iii ) receptor internalization; and ( iv ) activation of extracellular regulated kinase 1/2 (ERK 1/2), which is maintained in the G protein-uncoupled mutant β2AR T68F,Y132G,Y219A (β2AR TYY ) and abolished by β-arrestin2 siRNA. Taken together, these data indicate that carvedilol is able to stabilize a receptor conformation which, although uncoupled from G s , is nonetheless able to stimulate β-arrestin-mediated signaling. We hypothesize that such signaling may contribute to the special efficacy of carvedilol in the treatment of heart failure and may serve as a prototype for a new generation of therapeutic β2AR ligands.
Stroke Symptoms in Individuals Reporting No Prior Stroke or Transient Ischemic Attack Are Associated With a Decrease in Indices of Mental and Physical Functioning
Howard, George , Safford, Monika M. , Moy, Claudia S., Howard, Virginia J. , Pulley, LeaVonne, Crowther, Martha R., Meschia, James F. , Gomez, Camilo R. , Howard, Virginia J , Howard, George

Mayo Clinic

Stroke | August 3, 2007 | Volume: 38 | Issue: 9 | Pages: 2446-2452

10.1161/strokeaha.106.478032 | PMID 17673720 Get It

Background and Purpose— Stroke symptoms in the absence of recognized stroke are common, but potential associated dysfunctions have not been described. Methods— We assessed quality-of-life measures using the Physical and Mental Component Summary scores of the Short Form 12 (PCS-12 and MCS-12) in the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. Differences in mean PCS-12 and MCS-12 scores were assessed among participant groups symptoms-free (n=16 090); history of stroke symptoms but free of stroke/transient ischemic attack (n=3404); history of stroke (n=1491); and history of transient ischemic attack (n=818). Results— Participants with symptoms (but no diagnosis) had average PCS-12 scores 5.5 (95% CI: 5.2 to 5.9) points lower than those without symptoms, a difference similar to transient ischemic attack (6.0; 95% CI: 5.3 to 6.7) and over one half the effect of stroke (8.4; 95% CI: 8.0 to 9.0). MCS-12 scores were 2.7 (95% CI: 2.4 to 3.0) points lower for those with symptoms, −0.5 for transient ischemic attack (95% CI: 0.0 to −1.1), and −1.6 for stroke (95% CI: −1.2 to −2.0). Differences in demographic and vascular risk factors, health behaviors, physiological measures, and indices of socioeconomic status did not fully explain these differences. Those reporting history of weakness or numbness had larger current decrements in physical functioning, and those reporting history of inability to express themselves or understand language had larger current decrements in mental functioning. Conclusions— Individuals with clinically consistent symptoms but no stroke diagnosis have a lower quality of life than those without symptoms. The difference in physical functioning is substantial with a smaller decline in mental functioning. Apart from so-called “silent stroke,” there appear to be many individuals with possibly symptomatic cerebrovascular disease—either stroke or transient ischemic attack—who are not being diagnosed. Furthermore, these symptomatic but undiagnosed strokes may not be benign.
Use of Calcium and Magnesium Salts to Reduce Oxaliplatin-Related Neurotoxicity
Höchster, Howard S. , Childs, Barrett H. , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | July 31, 2007 | Volume: 25 | Issue: 25 | Pages: 4028-4029

10.1200/jco.2007.13.5251 | PMID 17664456 Get It

Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma
Pelloski, Christopher E., Furth, Alfred, Zhang, Li , Sulman, Erik P. , Bhat, Krishna , McDonald, J. Matthew , Yung, W.K. Alfred, Colman, Howard , Woo, Shiao Y. , Heimberger, Amy B. , Suki, Dima , Prados, Michael D. , Chang, Susan M. , Barker, Fred G., Buckner, Jan C. , James, C. David , Aldape, Kenneth , Ballman, Karla V. , Lin, Eileen Eng Jia , Colman, Howard , Heimberger, Amy B. , Chang, Susan Marina , Sulman, Erik P

Mayo Clinic

Journal of Clinical Oncology | May 30, 2007 | Volume: 25 | Issue: 16 | Pages: 2288-2294

10.1200/jco.2006.08.0705 | PMID 17538175 Get It

Purpose The clinical significance of epidermal growth factor receptor variant III (EGFRvIII) expression in glioblastoma multiforme (GBM) and its relationship with other key molecular markers are not clear. We sought to evaluate the clinical significance of GBM subtypes as defined by EGFRvIII status. Patients and Methods The expression of EGFRvIII was assessed by immunohistochemistry in 649 patients with newly diagnosed GBM. These data were then examined in conjunction with the expression of phospho-intermediates (in a subset of these patients) of downstream AKT and Ras pathways and YKL-40 as well as with known clinical risk factors, including the Radiation Therapy Oncology Group's recursive partitioning analysis (RTOG-RPA) class. Results The RTOG-RPA class was highly predictive of survival in EGFRvIII-negative patients but much less predictive in EGFRvIII-positive patients. These findings were seen in both an initial test set (n = 268) and a larger validation set (n = 381). Similarly, activation of the AKT/MAPK pathways and YKL-40 positivity were predictive of poor outcome in EGFRvIII-negative patients but not in EGFRvIII-positive patients. Pair-wise combinations of markers identified EGFRvIII and YKL-40 as prognostically important. In particular, outcome in patients with EGFRvIII-negative/YKL-40–negative tumors was significantly better than the outcome in patients with the other three combinations of these two markers. Conclusion Established prognostic factors in GBM were not predictive of outcome in the EGFRvIII-positive subset, although this requires confirmation in independent data sets. GBMs negative for both EGFRvIII and YKL-40 show less aggressive behavior.
Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy
Stephenson, Andrew J. , Scardino, Peter T. , Kattan, Michael W. , Pisansky, Thomas M. , Slawin, Kevin M., Klein, Eric A. , Anscher, Mitchell S. , Michalski, Jeff M. , Lin, Daniel W. , Forman, Jeffrey D., Zeléfsky, Michael J. , Kestin, Larry L. , Roehrborn, Claus G. , Catton, Charles , DeWeese, Theodore L. , Liauw, Stanley L. , Valicenti, Richard K., Kuban, Deborah A., Pollack, Alan , Sandler, Howard M. , Klein, Eric A , Liauw, Stanley L , Kattan, Michael W

Mayo Clinic

Journal of Clinical Oncology | May 19, 2007 | Volume: 25 | Issue: 15 | Pages: 2035-2041

10.1200/jco.2006.08.9607 | PMID 17513807 Get It

Purpose An increasing serum prostate-specific antigen (PSA) level is the initial sign of recurrent prostate cancer among patients treated with radical prostatectomy. Salvage radiation therapy (SRT) may eradicate locally recurrent cancer, but studies to distinguish local from systemic recurrence lack adequate sensitivity and specificity. We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence. Patients and Methods Using multivariable Cox regression analysis, we constructed a model to predict the probability of disease progression after SRT in a multi-institutional cohort of 1,540 patients. Results The 6-year progression-free probability was 32% (95% CI, 28% to 35%) overall. Forty-eight percent (95% CI, 40% to 56%) of patients treated with SRT alone at PSA levels of 0.50 ng/mL or lower were disease free at 6 years, including 41% (95% CI, 31% to 51%) who also had a PSA doubling time of 10 months or less or poorly differentiated (Gleason grade 8 to 10) cancer. Significant variables in the model were PSA level before SRT (P < .001), prostatectomy Gleason grade (P < .001), PSA doubling time (P < .001), surgical margins (P < .001), androgen-deprivation therapy before or during SRT (P < .001), and lymph node metastasis (P = .019). The resultant nomogram was internally validated and had a concordance index of 0.69. Conclusion Nearly half of patients with recurrent prostate cancer after radical prostatectomy have a long-term PSA response to SRT when treatment is administered at the earliest sign of recurrence. The nomogram we developed predicts the outcome of SRT and should prove valuable for medical decision making for patients with a rising PSA level.